


PHARMACEUTICAL 2023


Ovid Therapeutics Inc. Rank 103 of 446







PHARMACEUTICAL 2023





The relative strengths and weaknesses of Ovid Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ovid Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 62% points. The greatest weakness of Ovid Therapeutics Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 21% points.

The company's Economic Capital Ratio, given in the ranking table, is 194%, being 151% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	131,381
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,992
Liabilities, Non-Current	16,002
Other Assets	22,737
Other Compr. Net Income	-42
Other Expenses	0
Other Liabilities	0
Other Net Income	1,379
Other Revenues	1,503
Property and Equipment	1,148
Research and Development	24,618
Selling, General and Administrative Expense	32,433

Output Variable	Value in 1000 USD
Assets	155,266
Liabilities	22,993
Expenses	57,051
Revenues	1,503
Stockholders Equity	132,273
Net Income	-54,169
Comprehensive Net Income	-54,190
Economic Capital Ratio	194%

